◆ NeutralCMND
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
GlobeNewswire Inc.·
Clearmind Medicine Inc. (Nasdaq: CMND) filed a patent application with the Hong Kong Patent Office for innovative psychedelic compounds targeting PTSD treatment. The filing is part of an exclusive licensing agreement with Yissum Research Development Company of Hebrew University. The global PTSD treatment market is valued at USD 18.5 billion in 2025 and projected to reach USD 30.2 billion by 2035, with Clearmind positioning Hong Kong as a strategic gateway for Asian market access.
Read Full Article at GlobeNewswire Inc. →